SuperworthStructure Therapeutics EPS GPCR
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- −$1.04
- Latest quarter, Q2 FY26
- −$0.49
- Fiscal year 2025
- −$0.83
Structure Therapeutics' earnings per share was −$1.04 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.49.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.83 | n/a |
| FY2024 | −$0.78 | n/a |
| FY2023 | −$0.84 | n/a |
| FY2022 | −$5.53 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.49 | n/a | −$1.04 | |
| Q1 FY26 | −$0.35 | n/a | −$0.91 | |
| Q4 FY25 | $0.17 | n/a | −$0.83 | |
| Q3 FY25 | −$0.37 | n/a | −$1.21 | |
| Q2 FY25 | −$0.36 | n/a | −$1.04 | |
| Q1 FY25 | −$0.27 | n/a | −$0.86 | |
| Q4 FY24 | −$0.21 | n/a | −$0.78 | |
| Q3 FY24 | −$0.20 | n/a | −$0.75 | |
| Q2 FY24 | −$0.18 | n/a | −$0.76 | |
| Q1 FY24 | −$0.19 | n/a | −$0.78 | |
| Q4 FY23 | −$0.18 | n/a | −$0.84 | |
| Q3 FY23 | −$0.21 | n/a | −$1.84 |
Against its peers
Companies in Drug Manufacturers - General nearest Structure Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| GPCRStructure Therapeutics | −$1.04 | |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| OMEROmeros | $1.52 | |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| ABUSArbutus Biopharma | $0.78 | |
| NRIXNurix Therapeutics | $2.31 | |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Structure Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.